Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain.

Excitotoxic damage may be a critical factor in the formation of brain lesions associated with cerebral palsy. When injected at birth, the glutamatergic analog ibotenate induces mouse brain lesions that strikingly mimic human microgyria. When ibotenate is injected at postnatal day 5, it produces transcortical necrosis and white matter cysts that mimic human perinatal hypoxic-like lesions. Vasoactive intestinal peptide (VIP) has potent growth-related actions and neuroprotective properties that influence mitosis and neuronal survival in culture. The goal of this study was to assess the protective role of VIP against excitotoxic lesions induced by ibotenate in developing mouse brain. VIP cotreatment reduced ibotenate-induced microgyric-like cortical lesions and white matter cysts by up to 77 and 85%, respectively. VIP protective effects were reproduced by a peptide derived from activity-dependent neurotrophic factor (ADNF), a trophic factor released by VIP-stimulated astrocytes, and by stearyl norleucine VIP, a specific VIP agonist that does not activate adenylate cyclase. Neither forskolin, an adenylate cyclase activator, nor pituitary adenylate cyclase-activating peptide, provided VIP-like protection. VIP and neurotrophic analogs, acting through a cAMP-independent mechanism and inducing ADNF release, could represent new avenues in the understanding and prevention of human cerebral palsy.

[1]  P. Gressens,et al.  Growth Factor Properties of VIP during Early Brain Development , 1997, Annals of the New York Academy of Sciences.

[2]  M. Dehan,et al.  PERIVENTRICULAR LEUKOMALACIA: RISK FACTORS REVISITED , 1996, Developmental medicine and child neurology.

[3]  L. Wendt,et al.  The changing panorama of cerebral palsy in Sweden. VII. Prevalence and origin in the birth year period 1987‐90 , 1996, Acta paediatrica.

[4]  P. Nelson,et al.  Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting neurotrophic serpin, protease nexin I. , 1996, Journal of neurobiology.

[5]  I. Gozes,et al.  A femtomolar-acting neuroprotective peptide. , 1996, The Journal of clinical investigation.

[6]  S. Said,et al.  Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Ellison,et al.  Embryonic Expression of Vasoactive Intestinal Peptide (VIP) and VIP Receptor Genes , 1996, Journal of neurochemistry.

[8]  P. Gluckman,et al.  Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs. , 1996, The Journal of clinical investigation.

[9]  I. Gozes,et al.  Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Holtzman,et al.  Nerve growth factor protects the neonatal brain against hypoxic–ischemic injury , 1996, Annals of neurology.

[11]  D. Murphy,et al.  Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies , 1995, The Lancet.

[12]  P. Magistretti,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase‐Activating Polypeptide Potentiate c‐fos Expression Induced by Glutamate in Cultured Cortical Neurons , 1995, Journal of neurochemistry.

[13]  G. Glazner,et al.  Interleukin-1 alpha and vasoactive interstinal peptide: Enigmatic regulation of neuronal survival , 1995, International Journal of Developmental Neuroscience.

[14]  P. Gressens,et al.  PREVENTION BY MAGNESIUM OF EXOTOTOXIC NEURONAL DEATH IN THE DEVELOPING BRAIN: AN ANIMAL MODEL FOR CLINICAL INTERVENTION STUDIES , 1995, Developmental medicine and child neurology.

[15]  N. Aiyar,et al.  Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. , 1995, Biochemical and biophysical research communications.

[16]  I. Gozes,et al.  Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. , 1995, The Journal of pharmacology and experimental therapeutics.

[17]  W. Anderson,et al.  Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes , 1994, Journal of neuroscience research.

[18]  P. Gressens,et al.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. , 1994, The Journal of clinical investigation.

[19]  I. Gozes,et al.  Blockade of VIP during Neonatal Development Induces Neuronal Damage and Increases VIP and VIP Receptors in Brain , 1994, Annals of the New York Academy of Sciences.

[20]  I. Tatsuno,et al.  PACAP Functions as a Neurotrophic Factor a , 1994, Annals of the New York Academy of Sciences.

[21]  P. Gressens,et al.  Effect of Ibotenate on Brain Development: An Excitotoxic Mouse Model of Microgyria and Posthypoxic‐like Lesions , 1994, Journal of neuropathology and experimental neurology.

[22]  M. Sporn,et al.  Maternal rescue of transforming growth factor-beta 1 null mice. , 1994, Science.

[23]  I. Gozes,et al.  Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. , 1994, Endocrinology.

[24]  P. Gressens,et al.  Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: Relation to ontogenic events , 1994, The Journal of comparative neurology.

[25]  A. Fatatis,et al.  Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Fink,et al.  The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.

[27]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[28]  M. Thordstein,et al.  Scavengers of Free Oxygen Radicals in Combination with Magnesium Ameliorate Perinatal Hypoxic-Ischemic Brain Damage in the Rat , 1993, Pediatric Research.

[29]  E. Goetzl,et al.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.

[30]  P. Gressens,et al.  Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos , 1993, Nature.

[31]  T. Ulich,et al.  Granulocyte colony-stimulating factor crosses the placenta and stimulates fetal rat granulopoiesis. , 1993, Blood.

[32]  M. Hayashi.  Ontogeny of some neuropeptides in the primate brain , 1992, Progress in Neurobiology.

[33]  A. Arimura.  Receptors for pituitary adenylate cyclase-activating polypeptide Comparison with vasoactive intestinal peptide receptors , 1992, Trends in Endocrinology & Metabolism.

[34]  J. Hill,et al.  Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain , 1992, Neuroscience.

[35]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[36]  A. Barkovich,et al.  Formation, maturation, and disorders of brain neocortex. , 1992, AJNR. American journal of neuroradiology.

[37]  T. Moody,et al.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. , 1991, The Journal of pharmacology and experimental therapeutics.

[38]  I. Gozes,et al.  Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat , 1991, Peptides.

[39]  I. Gozes,et al.  A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes , 1991, Brain Research.

[40]  R W Cooke,et al.  Birthweight specific trends in cerebral palsy. , 1990, Archives of disease in childhood.

[41]  Michael V. Johnston,et al.  Physiological and pathophysiological roles of excitatory amino acids during central nervous system development , 1990, Brain Research Reviews.

[42]  D. Brenneman,et al.  Vasoactive intestinal peptide: A neurotrophic releasing agent and an astroglial mitogen , 1990, Journal of neuroscience research.

[43]  I. Black,et al.  Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts , 1990, Nature.

[44]  I. Gozes,et al.  Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist , 1989, Regulatory Peptides.

[45]  L. D. de Vries,et al.  Evolution of periventricular leukomalacia during the neonatal period and infancy: correlation of imaging and postmortem findings. , 1988, Early human development.

[46]  P. Hamilton,et al.  PRECISION OF ULTRASOUND DIAGNOSIS OF PATHOLOGICALLY VERIFIED LESIONS IN THE BRAINS OF VERY PRETERM INFANTS , 1988, Developmental medicine and child neurology.

[47]  J. Ellenberg,et al.  Antecedents of cerebral palsy. Multivariate analysis of risk. , 1986, The New England journal of medicine.

[48]  L. Eiden,et al.  Vasoactive intestinal peptide and electrical activity influence neuronal survival. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Siegel,et al.  Neurotrophic action of VIP on spinal cord cultures , 1985, Peptides.

[50]  G. Hagberg,et al.  The Changing Panorama of Cerebral Palsy in Sweden , 1984, Acta paediatrica Scandinavica.

[51]  P. Magistretti,et al.  VIP and noradrenaline act synergistically to increase cyclic AMP in cerebral cortex , 1984, Nature.

[52]  J. Larsen,et al.  Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. , 1982, American journal of obstetrics and gynecology.

[53]  J. Moossy,et al.  Cerebral infarcts with arterial occlusion in neonates , 1979, Annals of neurology.

[54]  J. Volpe,et al.  Perinatal hypoxic-ischemic brain injury. , 1976, Pediatric clinics of North America.

[55]  J. Volpe.  Neurology of the Newborn , 1959, Major problems in clinical pediatrics.

[56]  G. Glazner,et al.  Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. , 1996, The Journal of clinical investigation.

[57]  T. Buchanan,et al.  Access of maternal insulin to the rat conceptus prior to allantoic placentation. , 1989, Diabetes research (Edinburgh, Scotland).

[58]  M. Obregon,et al.  L-thyroxine and 3,5,3'-triiodo-L-thyronine in rat embryos before onset of fetal thyroid function. , 1984, Endocrinology.

[59]  V. Caviness,et al.  Normal and Abnormal Development of the Brain , 1984 .

[60]  E. Page,et al.  Human reproduction: Essentials of reproductive and perinatal medicine , 1981 .